Tetrahydroxyquinone之眼科的應用

Tetrahydroxyquinone in Ophthalmic Use

陳振武(Chen-Wu Chen)

《中華民國眼科醫學會會刊》 5卷 (1966/05) Pp. 38-44

https://doi.org/10.30048/ACTASOS.196605.0006

並列摘要

Suggested by Sheridan, tetrahydroxyquinone (THQ), a redox acting substance, was first introduced into clinical use by Kelly and Piukus for the oral treatment of kelloids. They stated (1) that kelloids of all ages shoved some response to this drug, (2) that THQ was selective in its action, and (3) that the effect of THQ m gat be mediated by enzymatic action.
Owing to its delicate structure and specific visual function of the eye, the resulted fibrosis or scarring of its tissues after prolonged and destructive lesions usually leads to the permanent impairment of the visual function. This is particularly true when the lesion affects the cornea or the retina in the area along the visual line. Once the fibrous scar is formed in the eye tissues, the resulted impairment of the visual function is usually permanent. Improvement of the vision hardly takes place with the use of our conventional ways of ophthalmic treatment. In treating eye diseases attempts should be made to reduce the subsequent and excessive fibrous proliferation in order to limit the resulting impairment of the visions to the least degree.
The author has applied THQ to various eye diseases for the past year. Unexpected successes were experienced. Seven representative cases with success, among that were two of corneal opacities of trachomatous and stromal herpes simplex origin, two of proliferative lesion of the retina in the macular area after trauma, one of viterous opacity caused by posterior uveitis, and two of retinal hemorrhages caused by the thrombotic lesion of the retinal veins, were reported.
In all cases reported improvement of visions that had been static for certain period of time during the conventional treatment, took place evidently one to three weeks after the administration of THQ. The longstanding corneal opacity restored its transparency in both eyes in one case to certain degree. The vitreous floaters were absorbed more rapidly. The retinal hemorrhages were absorbed more or less completely leaving behind only few puntate and linear white opacities.
The introduction of redo acting substances into clinical use for the prevention and treatment of resulting and resulted fibrous proliferative processes after eye diseases may add a new weapon to our therapeutic armamentum in ophthalmology.